The New York Heart Association recommends that TNF-α inhibitors are contraindicated in patients with class 3 or 4 CHF as well as those with class 1 or 2 CHF whose ejection fraction is lower than 50% (Menter et al., 2008). The gene discussed is TNF; the disease is congestive heart failure.